Clinical Trial of Black Seeds Against COVID

Nigella Sativa study #2 of 4 All Outcomes

1/31 Early treatment study

Al-Haidari et al., Indian Journal of Forensic Medicine & Toxicology, 15:3 (preprint 1/2021) (Peer Reviewed)
Clinical Trial of Black Seeds Against COVID – 19 in Kirkuk City / Iraq

Source PDF Share Tweet

Open-label RCT with 419 patients in Iraq, 160 treated with Nigella Sativa, showing lower mortality and severe cases with treatment.

Al-Haidari et al., 1/31/2021, Randomized Controlled Trial, Iraq, Middle East, peer-reviewed, 3 authors.

risk of death, 95.8% lower, RR 0.04, p = 0.001, treatment 0 of 160 (0.0%), control 14 of 259 (5.4%), continuity correction due to zero event (with reciprocal of the contrasting arm).

risk of COVID-19 severe case, 92.6% lower, RR 0.07, p < 0.001, treatment 2 of 160 (1.2%), control 44 of 259 (17.0%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 4 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit